Dear Members,
Your Directors take immense pleasure in presenting the 40 Annual Report
on the business and operations of the Company, along with the Audited Financial Statements
(Standalone and Consolidated) for the Financial Year ended March 31, 2024.
FINANCIAL SUMMARY AND HIGHLIGHTS
The Standalone and Consolidated Financial Statements of the Company for
the year ended March 31, 2024, have been prepared in accordance with the Indian Accounting
Standards (Ind AS), Section 133 and other applicable provisions of the Companies Act, 2013
(Act) as well as the relevant applicable provisions of the Securities and
Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015 (SEBI Listing Regulations) and subsequent amendments thereto.
The key highlights of financial performance of the Company, for the
financial year ended March 31, 2024 is summarized below:
( in Lakhs)
Particulars |
Standalone |
Consolidated |
|
2023-24 |
2022-23 |
2023-24 |
Total Revenue from Operations |
80,666.57 |
69,062.08 |
80,666.57 |
Other Income |
217.72 |
257.39 |
217.72 |
Total Income |
80,884.29 |
69,319.47 |
80,884.29 |
Profit / (Loss) before
Depreciation & Amortization, Finance Cost, exceptional item and tax |
14,804.86 |
13,722.52 |
14,804.86 |
(Less): Depreciation and Amortization expense |
1,701.72 |
2,228.10 |
1,701.72 |
(Less): Finance Costs |
1,535.99 |
822.33 |
1,535.99 |
Profit / (Loss) before Exceptional items
and Tax |
11,567.15 |
10,672.09 |
11,567.15 |
Add /(Less): Exceptional items |
- |
- |
- |
Profit / (Loss) before tax |
11,567.15 |
10,672.09 |
11,567.15 |
(Less): Tax Expense: Current Tax |
2,840.00 |
2,821.00 |
2,840.00 |
Deferred Tax |
316.54 |
(119.39) |
316.54 |
Income Tax earlier years |
(202.95) |
- |
(202.95) |
Profit / Loss for the year (1) |
8,613.55 |
7,970.48 |
8,613.55 |
Other Comprehensive Income / (Loss) (2) |
(40.39) |
(0.53) |
(40.39) |
Total Comprehensive Income (1+2) |
8,573.17 |
7,969.95 |
8,573.17 |
FINANCIAL PERFORMANCE AND THE STATE OF COMPANY'S AFFAIRS
The Company's total revenue from operations stood at 80,667.57
lakhs in the financial year 2023-24, thereby showing an increase as compared to 69,062.08
lakhs in the previous financial year 2022-23. The Profit before Interest, Tax,
Depreciation & Amortization (EBIDTA) was Rs. 14,804.86 lakhs in the year under review
as compared to 13,722.52 lakhs in the financial year 2022-23. However, the EBIDTA margin
for the financial year 2023-24 was18.4% as compared to 19.8% in the previous financial
year.
During the year, the domestic market accounted for 89.07% of the
Company's turnover, with exports contributing 10.93%. Going forward, the Company is
focused on expanding its revenue from the export market.
The Net Profit of the Company, during the year under review, was
8,613.55 lakhs as compared to 7,970.48 lakhs in the previous financial year.
The Consolidated financial statements comprise of financials of the
Company and its subsidiary company in United Kingdom viz., Gufic UK Limited. Since, there
was no activities undertaken by the said subsidiary in the financial year 2023-24, the
total revenue and profit remain consistent across both Standalone and Consolidated
Financials.
Overall, the financial year 2023-2024 was positive for the Company,
reflecting strong financial performance and notable strides in strategic growth. The
Company is steadfast in its commitment to providing innovative and high-quality healthcare
solutions while maximizing value for our stakeholders.
A detailed analysis of performance for the year including the major
developments, if any, has been included in the Management Discussion and Analysis Report,
which forms a part of the Annual Report.
CHANGE IN THE NATURE OF BUSINESS
There was no change in the nature of business during the year under
review and it continues to operate only in one segment i.e. Pharmaceutical.
TRANSFER TO RESERVES
During the financial year under review, the Company has not proposed to
transfer any amount to the General Reserve.
DIVIDEND
Your Board of Directors are pleased to recommend a final dividend of
0.10 /- (10%) per equity share having face value of 1/- each fully paid-up for the
financial year ended March 31, 2024, subject to the approval of members at the ensuing 40
Annual General Meeting (AGM). The Final Dividend, if approved, will be paid,
within 30 (thirty) days from the date of the AGM to those Members whose name appears in
the Register of Members as on the book closure date mentioned in the Notice convening the
AGM. In view of the changes made under the Income Tax Act, 1961, dividends paid or
distributed by the Company shall be taxable in the hands of the Members, therefore, the
Company shall, accordingly, make the payment of the Dividend after deduction of tax at
source.
The total dividend pay-out for the financial year ending March 31, 2024
would amount to Rs. 1,00,27,750.60/-.This recommended dividend pay-out is in accordance
with the Company's Dividend Distribution Policy, details of which is available on the
website of the Company and the same can be accessed at following link:
http://gufic.com/wp-content/uploads/2021/08/Dividend%20Distribution%20Policy.pdf
SHARE CAPITAL
During the period under review, the Company has neither issued any
equity shares with differential voting rights as to dividend, voting or otherwise nor
granted any stock options nor sweat equity shares nor made any provision of money for
purchase of its own shares by employees or by trustees for the benefit of employees nor
bought back its shares.
(I)ISSUE OF EQUITY SHARES ON PREFERENTIAL BASIS
During the year under review, your Company issued and allotted
33,33,000 fully paid-up equity shares of the Company having face value of 1/- each at the
price of 300/- (Rupees Three Hundred Only) per equity share including premium of 299/-
(Rupees Two Hundred And Ninety-Nine Only) per equity share to M/s. Motilal Oswal Financial
Services Limited, Non Promoter of the Company on a preferential basis. The details
regarding the utilization of funds raised through the aforementioned preferential
allotment are provided in the Report on Corporate Governance , which forms part of this
Annual Report.
The aforesaid newly issued shares rank pari-passu in all aspects with
the existing equity shares of the Company.
Post Completion of the issuance, the Issued, Subscribed and Paid up
share capital of the Company has increased from 9,69,44,506/- divided into 9,69,44,506
Equity Shares of face value of 1/- each to 10,02,77,506/- divided into 10,02,77,506 Equity
Shares of face value of 1/- each. There has been no change in the authorized share capital
of the Company.
(II)GUFIC BIOSCIENCES LIMITED EMPLOYEES STOCK OPTION PLAN 2023
The Gufic Biosciences Limited Employees Stock Option Plan 2023
(Gufic ESOP 2023) was duly approved by the shareholders at its 39 AGM held on
September 29, 2023. Your Company has subsequently obtained In-Principle Approval from BSE
Limited (BSE) & National Stock Exchange of India Limited (NSE)
to issue, grant, offer and allot at any time, Stock Options to eligible employees not
exceeding 5,00,000 Stock Options convertible into equivalent number of equity shares, upon
exercise.
Gufic ESOP 2023 is designed to reward, retain and engage employees
while fostering a sense of ownership, performance, and alignment with the Company's
long-term goals. This strategic initiative aims to encourage sustained contributions
towards the Company's growth and profitability.
The Nomination & Remuneration Committee of your Company, designated
as Compensation Committee, oversees the administration and monitoring of Gufic ESOP 2023,
implemented by your Company in accordance with the Act and the SEBI (Share Based Employee
Benefits and Sweat Equity) Regulations, 2021, as amended from time to time (the SEBI
SBEB & SE Regulations).
The Nomination & Remuneration Committee, designated as Compensation
Committee, at their meeting held on June 27, 2024 has approved grant of 6,000 (Six
thousand) stock options under Gufic ESOP 2023 to the eligible employees.
A certificate from the Secretarial Auditor in accordance with
Regulation 13 of the SEBI SBEB & SE Regulations is annexed to this report as Annexure
A and can also be accessible on the Company's website at following link:
http://gufic.com/Notice/SBEB_Certificate_2024.pdf
SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES:
During the period under review, the Company has 3 (three) foreign
Wholly Owned Subsidiaries and 1 (one) Indian Subsidiary. The details are as below:
Name of the Company |
Country |
Incorporation Date |
Gufic UK Limited (GUL) |
United Kingdom |
15.03.2022 |
Gufic Ireland Limited (GIL) |
Ireland |
02.03.2023 |
Gufic Prime Private Limited (GPPL) |
India |
18.11.2023 |
Veira Life FZE (VLF) |
Dubai |
25.03.2024 |
- As of March 31, 2024, neither investment have been made in GIL, GPPL
and VLF nor they have begun their business operations. Consequently, there was no need to
consolidate the accounts of GIL, VLF and GPPL with the Company for the financial year
ending March 31, 2024.
- On September 13, 2023, the Company made an investment in GUL by
subscribing to its shares. Consequently, the consolidated financial results for the
financial year ended March 31, 2024, have been prepared by the Company considering the
financials of GUL.
- In order to enhance the operational flexibility for GUL, the Board of
Directors of the Company considered and approved further investment in GUL for the amount
of 49,000 pounds and consequently increase the Subscribed Share Capital of GUL from 1000
Ordinary shares of 1 pound each to 50,000 Ordinary shares of 1 pound each. The additional
capital was invested by the Company on July 12, 2024.
- On April 25, 2024, the Company made an investment in GPPL by
subscribing to its shares aggregating to 88% of its total paid up share capital.
In accordance with Section 129(3) of the Act, the Consolidated
Financial Statements of the Company has been prepared and forms part of the Annual Report.
Further, a separate statement containing the salient features of financial statements of
subsidiary in the prescribed Form AOC-1 is annexed to this report as Annexure
B.
As on March 31, 2024, the Company has no material subsidiaries.
Further, the Company's Policy on Material Subsidiaries can be accessed at
http://gufic.com/wp-content/uploads/2022/07/Policy_on_Material_Subsidiary.pdf
In accordance with fourth proviso of Section 136(1) of the Act, the
Annual Report of the Company, containing therein its standalone and the consolidated
financial statements has been placed on the website of the Company at www.gufic.com.
Further, as per fifth proviso of the said section, audited annual accounts of each of the
subsidiary companies have also been placed on the website of the Company at
https://gufic.com/media/investors/gufic-uk-limited/. Shareholders interested in obtaining
a physical copy of the audited annual accounts of the subsidiary companies may write to
the Company Secretary at mgrfilegal@guficbio.com / corporaterelations@guficbio.com.
Your Company does not have any Associate Company or Joint Venture.
Further, no Company ceased to be Subsidiary or Associate or Joint Venture of the Company,
during the financial year under review.
DIRECTORS AND KEY MANAGERIAL PERSONNEL
Appointment / Re-appointment / Continuation Of Directorship
During the year under review, the Board at its meeting held on August
11, 2023 and shareholders at its 39 AGM of the Company held on September 29, 2023 through
Special Resolution, approved the continuation of directorship of the following directors:
O Mr. Jayesh P. Choksi (DIN: 00001729) as Chairman & Managing
Director of the Company on attaining the age of 70 yearson March 29, 2024, on the existing
terms and conditions duly approved in the 35 AGM held on September 30, 2019.
O Mr. Gopal M. Daptari (DIN: 07660662) as a Non-Executive Independent
Director of the Company who shall attain the age of 75 years on October 29, 2024, until
the expiry of his current term.
The following Directors are proposed to be appointed/ re-appointed at
the ensuing AGM, the brief details of which arementioned in the Notice of 40 AGM forming
part of this Annual Report:
Appointment
O The Board of Directors of the Company at its Meeting held on June 27,
2024, approved appointment of Mr. Kamal Kishore Seth (DIN: 00194986), who has attained the
age of 75 years, as an Additional Director in the category of Non Executive Independent
Director, not liable to retire by rotation, to hold office for the term of 5 (five)
consecutive years with effect from June 27, 2024, subject to the approval of the
shareholders at the ensuing AGM through special resolution. Upon receipt of the said
shareholder's approval, Mr. Seth shall be re-designated as an Independent Director of
the Company for the term of 5 years with effect from June 27, 2024.
Re- appointment
O The Board of Directors at its Meeting held on August 14, 2024
approved re-appointment of Mr. Jayesh P. Choksi (DIN: 00001729) as a Chairman &
Managing Director, who has attained the age of 70 years for a period of 5 (five)
yearscommencing from 1 April, 2025 to 31 March, 2030 (both days inclusive)on the terms and
conditions mentioned in theNotice convening the 40 AGM, subject to the approval of the
shareholders through special resolution.
O The Board of Directors at its Meeting held on August 14, 2024
approved re-appointment of Mr. Pranav Choksi (DIN: 00001731) as a Whole Time Director
designated as Whole Time Director and Chief Executive Officer for a period of
5(five) years commencing from 1 April, 2025 to 31 March, 2030 (both days inclusive)on the
terms and conditionsmentioned in the Notice convening the 40 AGM, subject to the approval
of the shareholders through special resolution.
Cessation
O With deep regret, we report the sad demise of our Independent
Director Mr. Shrirang Vaidya (DIN: 03618800), on April 01, 2024. His sudden and unexpected
demise is an irreparable loss to the Company. The Board of Directors and Employees of the
Company extend heartfelt sympathy, sorrow and condolences to his family.
O Mr. Dilip Ghosh (DIN: 00412406) resigned as a Whole Time Director
(Key Managerial Personnel) of the Company with effect from close of business hours on June
27, 2024, owing to his health issues.
O Dr. Rabi Sahoo (DIN: 01237464) ceased to be the Independent Director
of the Company with effect from close of business hours on June 28, 2024, due to
completion of his second term as an Independent Director.
Your Directors would like to place on record their highest gratitude
and appreciation for the guidance given by the aforesaid officials to the Board during
their association as directors of the Company.
During the year under review, there were no cessation of any of the
Directors. Apart from above, there were no changes in the Directors or Key Managerial
Personnel of the Company.
Re-appointment of Director retiring by Rotation
In accordance with the provisions of Section 152(6) of the Act read
with the rules made thereunder and in terms of Articles of Association of the Company, Mr.
Pankaj Gandhi (DIN :00001858), Whole Time Director of the Company is liable to retire
byrotation at the ensuing 40 AGM and being eligible, offered himself for re-appointment.
The Board of Directors, on the recommendation of the Nomination and Remuneration Committee
(NRC) has recommended his appointment.
The disclosures required pursuant to Regulation 36 of the SEBI Listing
Regulations read with Secretarial Standard 2 on General Meetings relating to the aforesaid
appointment/re-appointment of directors are given in the Notice of AGM.
Key Managerial Personnel (KMP)
Pursuant to Section 203 of the Act, the Key Managerial Personnel
(KMP's) of the Company as on date of this report are Mr. Jayesh P.
Choksi, Chairman & Managing Director; Mr. Pranav J. Choksi, Chief Executive Officer
and Whole Time Director; Mr. Pankaj J. Gandhi, Whole Time Director; Mr. Devkinandan B.
Roonghta, Chief Financial Officer and Ms. Ami N. Shah, Company Secretary & Compliance
Officer.
DECLARATION BY INDEPENDENT DIRECTORS
The Company has received declarations from all the Independent
Directors confirming that they meet the criteria of independence as prescribed under the
provisions of the Act, read with the schedules and rules issued thereunder, as well as
Regulation 16(1)(b) of the SEBI Listing Regulations (including any statutory
modification(s) or re-enactment(s) thereof for the time being in force). In terms of
Regulation 25(8) of the SEBI Listing Regulations, the Independent Directors have confirmed
that they are not aware of any circumstance or situation, which exist or may be reasonably
anticipated, that could impair or impact their ability to discharge their duties with an
objective independent judgement and without any external influence.
All Independent Directors of the Company have registered themselves
with the Indian Institute of Corporate Affairs (IICA) and have passed the
proficiency test, if applicable. They have also confirmed compliance of Schedule IV of the
Act and the Company's Code of Conduct.
Based on disclosures provided by them, none of them are
disqualified/debarred from being appointed or continuing as Directors of the Company by
any order of Ministry of Corporate Affairs / SEBI or any other statutory authorities.
In the opinion of the Board, all the Independent Directors of the
Company possess the highest standard of integrity, relevant expertise and experience,
including the proficiency required to best serve the interest of the Company.
POLICY ON APPOINTMENT AND REMUNERATION OF DIRECTORS
The Company has in place a Policy on criteria for Appointment of
Directors, KMP's and Senior Management Personnel and Evaluation of their performance.
The Policy is available on the Company's website and can be accessed at
http://gufic.com/wp-content/uploads/2016/08/AppointmentofDirectorsKMP201718.pdf
The said Policy lays down guiding principles for selection and
appointment of Directors, KMP's and Senior ManagementPersonnel and for determining
qualifications, positive attributes and formulating Remuneration Policy for Executive and
Non-Executive Directors of the Company.
The details of the said policy are included in the Report on Corporate
Governance forming part of this Report. There has been no change in the aforesaid policy
during the year under review.
Further, neither the Managing Director nor its Whole Time Director
draws any remuneration or commission from any of the subsidiary companies.
FAMILIARIZATION PROGRAMME OF INDEPENDENT DIRECTORS
In compliance with the requirements of Regulation 25(7) of SEBI Listing
Regulations, the Company has put in place a Familiarization Programme for the Independent
Directors to familiarise them with the Company, nature of industry in which the Company
operates, business model, risks and challenges associated with the business and such other
relevant information, which would enable them to take well informed decisions, discharge
the responsibilities and functions conferred on them. Details of Familiarisation Programme
imparted during the financial year under review has been uploaded on the Company's
website and can be accessed at
http://gufic.com/wp-content/uploads/2024/04/Familarisation%20Programme%202023-24.pdf
Your Company ensures that every new Independent Director upon
appointment to the Board, undergoes an introductory programme designed to familiarize them
with the Organization. This includes visits to the manufacturing plant, interactive
sessions with functional heads through which they can understand the Company's
objective, business operations, current progress and future prospects etc. Further, during
the meeting of the Board, the Directors receive comprehensive updates on Company
performance, industry scenario, business strategy, associated risks, relevant statutory
amendments, Company's policies and procedures, etc.
The format of the terms and conditions outlined in the letter of
appointment, which defines their role, function, duties and responsibilities, provided at
the time of appointment can be accessed at following link:
PERFORMANCE EVALUATION
In compliance with the provisions of the Act and the SEBI Listing
Regulations, the Board has carried out the Annual Performance evaluation of Individual
Directors, Committees of the Board and the Board as a whole in accordance with the
framework and criteria laid down by the NRC. A structured questionnaire was prepared
separately for the Board, Committees and Individual Directors, inter-alia covering various
parameters viz. composition and structure of the Board, responsibilities, attendance
including participation of the Directors at the Board and Committee meetings, governance
and compliance as a whole, quality of deliberations and effectiveness of the procedures
and all other factors. The above criteria are broadly based on the SEBI Guidance Note on
Board Evaluation.
The performance evaluation of the Independent Directors was carried out
by the entire Board, excluding the Director being evaluated. Further, Independent
Directors at their separate meeting had evaluated performance of Non-Independent
Directors, Board as a whole, Chairman of the Board and assessed the quality, quantity and
timeliness of flow of information between the Company management and the Board.
The manner in which the evaluation has been carried out and matters
incidental thereto, have been detailed in the Report on Corporate Governance, which forms
part of this report.
NUMBER OF MEETINGS OF THE BOARD
The Board of Directors met 7 (Seven) times during the year under
review. Details of the meetings of the Board of Directors along with other details are
provided in the Report on Corporate Governance, which forms part of this Report. The
intervening gap between the two consecutive Board meetings did not exceed 120 days as
prescribed under Section 173 of the Act, Regulation 17 of SEBI Listing Regulations and
Secretarial Standard on Board Meetings (SS-1) issued by the Institute of Company
Secretaries of India (ICSI).
COMMITTEES OF THE BOARD
During the year under review, the Board of Directors at its meeting
held on May 29, 2023 have constituted the Executive Committee to expedite all matters
relating to business operations and for dealing with various urgent operational matters.
This includes availing banking facilities, opening bank accounts, delegating operational
powers to the employees, appointing authorized representatives to represent the Company
before various statutory authorities and other routine administrative matters.
To effectively discharge the obligations and to comply with the
statutory requirements, the Company has in place 6 (six) Committees of the Board as on
March 31, 2024 viz.:
1. Audit Committee;
2. Corporate Social Responsibility Committee; 3. Nomination &
Remuneration Committee;
4. Risk Management Committee;
5. Stakeholders' Relationship Committee; and 6. Executive Committee
The details of all the Committees along with their composition, terms
of reference, meetings held during the year and attendance at the meetings are disclosed
in the Report on Corporate Governance that forms part of this Annual Report.
AUDIT COMMITTEE
As on March 31, 2024, the Audit Committee comprises of 6 (Six) members
which is in compliance with the provisions of the Act and SEBI Listing Regulations. The
details pertaining to composition of the Audit Committee along with other details are
included in the Report on Corporate Governance, which forms part of this Annual Report.
MEETING OF INDEPENDENT DIRECTORS
In terms of requirements under Schedule IV of the Act and Regulation
25(3) of SEBI Listing Regulations, a separate meeting of the Independent Directors was
held on November 09, 2023. The details of the meeting held are included in the Report on
Corporate Governance, which forms part of this report.
CODE OF CONDUCT
The Board of Directors at its meeting held on August 11, 2023 amended
the Code of Conduct for the Board of Directors and Senior Management (Code)
including a revised definition of senior management. The Code places a strong emphasis on
maintaining integrity in both workplace and business practices, promoting honest and
ethical conduct, and fostering diversity and fairness, among other important principles.
The Code can be accessed at following link:
The members of the Board and Senior Management of your Company have
submitted their affirmation on compliance with the Code of Conduct of the Company during
the Financial Year 2023-24, as required under the provisions of SEBI Listing Regulations.
A declaration to that effect duly signed by Mr. Pranav J. Choksi, Chief Executive Officer
and Whole Time Director, pursuant to Regulation 17(5) read with Schedule V of the SEBI
Listing Regulations forms part of this Annual Report.
MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL
POSITION OF THE COMPANY BETWEEN THE END OF THE FINANCIAL YEAR AND DATE OF REPORT
There have been no material changes and commitments affecting the
financial position of the Company between the end of the financial year to which the
financial statement relates and date of this Report.
DIRECTOR'S RESPONSIBILITY STATEMENT
To the best of their knowledge and belief and according to the
information and explanations provided to them and pursuant to the provisions of Section
134(3) (c) read with Section 134(5) of the Act, your Directors hereby state and confirm
that:-
a. in the preparation of the annual accounts/financial statements for
the year ended March 31, 2024, the applicable accounting standards have been followed
along with proper explanations relating to material departures, if any;
b. they have selected such accounting policies and applied them
consistently and made judgements and estimates that are reasonable and prudent so as to
give a true and fair view of the state of affairs of your Company at the end of the
financial year March 31, 2024 and of the profit of your Company for that period;
c. proper and sufficient care has been taken for the maintenance of
adequate accounting records in accordance with the provisions of the Act for safeguarding
the assets of the Company and for preventing and detecting fraud and other irregularities;
d. the annual accounts/ financial statements have been prepared on a
going concern basis;
e. they have laid down internal financial controls to be followed by
the Company and that such internal financial controls are adequate and were operating
effectively; and
f. they had devised proper systems to ensure compliance with the
provisions of all applicable laws and that such systems were adequate and operating
effectively.
INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY
During the year under review, the Company has successfully implemented
Systems, Applications and Products in data processing (SAP) which has been
effectively utilized for day-to-day transaction, accounting and financial reporting.
Investment in advanced automation systems has streamlined accounting and financial closing
procedures across various domains, enhancing accuracy and expediting financial reporting
while minimizing manual intervention. Automated financial statement preparation ensures
end-to-end system-driven reporting across the Group, thereby reducing the potential for
manual errors.
The Company has adequate internal control system and mechanism which is
commensurate with nature of its business, size, scale and complexity of its operations.
The Company has implemented a comprehensive framework which includes formulation of
Standard Operating Procedures (SOPs), Procedures and Controls, which are regularly audited
to safeguard its assets, ensure the accuracy and reliability of financial reporting,
enhance operational efficiency and ensure compliance with applicable laws and regulations.
Clear roles and responsibilities have been defined for each process establishing
accountability and promoting efficiency throughout the organization. The Company has also
set up Management Information System (MIS) to facilitate informed decision making. The
Company continues to have periodical internal audits conducted of all its functions and
activities to ensure that systems and processes are followed across all areas.
Internal Financial Controls are an integral part of the risk management
framework and process that address financial and financial reporting risks. The Company
has in place adequate internal financial controls with reference to the Financial
Statement.
The management diligently considers and takes appropriate actions on
the recommendations made by the Internal Auditors, Statutory Auditors and the Audit
Committee. The Audit Committee on a quarterly basis reviews the adequacy and effectiveness
of the Company's Internal Controls and monitors the implementation of recommendations
of the Auditors, if any.
The Company believes that these systems provide reasonable assurance
that the Company's internal financial controls are adequate and are operating
effectively as intended.
REPORTING OF FRAUDS
During the year under review, none of the Auditors has reported to the
Audit Committee any instances of fraud committed in the Company by its officers or
employees, as required under Section 143 (12) of the Act.
DEPOSITS
During the financial year under review, your Company has not accepted
any deposits within the meaning of Section 73 of the Act read with the Companies
(Acceptance of Deposits) Rules, 2014. Accordingly, no amount on account of principal or
interest on public deposits was outstanding as on March 31, 2024.
PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS
Details of loans, guarantees and investments under the provisions of
Section 186 of the Act read with the Companies (Meetings of Board and its Powers) Rules,
2014, as on March 31, 2024, are set out in Notes to the Financial Statements of the
Company provided in this Annual Report.
INVESTOR EDUCATION AND PROTECTION FUND (IEPF)
Pursuant to provisions of Section 124 and other applicable provisions,
if any, of the Act read with the Investor Education and Protection Fund Authority
(Accounting, Audit, Transfer and Refund) Rules, 2016 (the IEPF Rules), all
unpaid or unclaimed dividends are required to be transferred by the Company to the IEPF,
established by the Government of India, after completion of 7 (seven) years. Accordingly,
during the year under review, unpaid or unclaimed dividend amounting to 43,042/- (Rupees
Forty-Three Thousand and Forty-Two Only) was transferred by the Company to the IEPF.
In accordance with the IEPF Rules, the shares on which the dividend has
not been paid or claimed by the shareholders for seven consecutive years or more shall
also be transferred to the demat account of the IEPF Authority. Accordingly, 5344
unclaimed shares were transferred to IEPF during the year under review.
The Company has issued individual notices to the members whose equity
shares are liable to be transferred to IEPF within the stipulated time frame in the
current financial year i.e. 2024-25 to claim their dividend on or before October 10, 2024.
Details of unclaimed dividends and shareholders whose shares are liable to be transferred
to IEPF, are uploaded on the website of the Company at
http://gufic.com/media/investors/unclaimed_shares/gufic-iepf/Transfer%20of%20Shares/
RELATED PARTY TRANSACTIONS
All contracts/arrangements/transactions entered by the Company during
the financial year under review with related parties were in its ordinary course of
business and on an arm's length basis and in accordance with the Company's
policy on Related Party Transactions.
The approval of the Audit Committee was sought for all Related Party
Transactions and prior omnibus approval is obtained for transactions which are repetitive
in nature and/ or entered in the ordinary course of business and are at arm's length.
A statement of related party transactions is placed before the Audit Committee and the
Board of Directors for their review on a quarterly basis. There are no materially
significant related party transactions made by the Company, which may have potential
conflict with the interest of the Company. All the related party transactions entered
during the year under review, were in compliance with the provisions of the Act and SEBI
Listing Regulations.
Apart from remuneration and sitting fees, there is no pecuniary
transaction with any director, which had potential conflict of interest with the Company.
During the period under review, the Company has not entered into any
contracts/ arrangements/ transactions with related parties which qualify as material in
accordance with the Policy of the Company on Materiality of Related Party Transactions and
hence there is no information to be provided in Form AOC-2 as required under Section
134(3)(h) read with Section 188 of the Act and Rule 8(2) of the Companies (Accounts)
Rules, 2014.
Policy on Related Party Transactions as formulated/ amended from time
to time, by the Board is available on the Company's website at
http://gufic.com/wp-content/uploads/2016/08/Related%20Party%20Transactions%20Policy.pdf
Attention of Members is also drawn to Note 39 of the Financial
Statements for the year ended March 31, 2024 which sets out the related party disclosures
as per the Ind AS-24.
CORPORATE SOCIAL RESPONSIBILITY INITIATIVES
The Company has constituted a Corporate Social Responsibility (CSR)
Committee in accordance with Section 135 of the Act. As on March 31, 2024, the CSR
Committee comprises of 4 (Four) members which is in compliance with the provisions of the
Act. The details pertaining to composition of the CSR Committee along with other details
are included in the Report on Corporate Governance, which forms part of this Annual
Report. The role of the Committee is to review the CSR Policy, indicate activities to be
undertaken by the Company towards CSR and formulate a transparent monitoring mechanism to
ensure implementation of projects and activities undertaken by the Company towards CSR.
The key philosophy of the CSR initiative of the Company is to promote
development through social and economic transformation. During the period under review,
the Company spent CSR amount in the areas of promoting healthcare, education, sports and
animal welfare. The CSR Policy of the Company are available on the website of the Company
and can be accessed at
http://gufic.com/wp-content/uploads/2021/08/Corporate%20Social%20Responsibility%20Policy.pdf
M/s. P S Choksi Foundation, a company limited by guarantee under
Section 8 of the Act, was incorporated on June 7, 2024. Your Company is a subscriber to
the Memorandum of Association of this foundation, which will serve as an implementing
agency for the Company's CSR activities as prescribed under Schedule VII of the Act.
The Annual Report on CSR containing, details of CSR Policy, composition
of CSR Committee, CSR expenditure and web-link thereto on the website of the Company, as
required under Companies (Corporate Social Responsibility Policy) Rules, 2014, is set out
in Annexure C of this Report.
CONSERVATION OF ENERGY
1. Steps taken by the Company or impact on conservation of energy
l Setting optimum frequency for all air conditioning units to
promote energy savings. Additionally, higher-efficiency air conditioning units have been
installed in to further enhance power savings.
l Have in place motion sensors for lighting load optimisation.
Higher-wattage CFL lights have been replaced with lower-wattage LED lights to support
power-saving efforts.
l Implementing energy-efficient practices by ensuring power factor
between 0.99 to 1.0
l Installation of energy meters for the new plant and new
machines to facilitate continuous monitoring of kilowatt-hours (kWh) and utilizing an
Online Energy Monitoring System to track daily consumption, enabling analysis and
reduction of excess power use by comparing it with production levels.
l Installed water level controllers and level sensors in the
bore well that supplies water to the facility to reduce water wastage.
l Automation panel with temperature sensors, flow meters and Variable
Frequency Drives (VFDs) has been designed for new cooling tower pumps and fans to support
energy-efficient operations for chillers.
2. Steps taken for utilizing alternate source of energy
l Replacing conventional fuels is a positive step towards adopting a
more sustainable and eco-friendly approach to energy consumption which includes
Transitioning to biomass briquettes for steam generation.
l Express feeders in main RAW power source has been treated beneficial
in terms of efficiency, reliability and overall power distribution system.
l Utilizing DG sets and UPS power as an alternative power sources to
ensure uninterrupted operations during power outages.
3. Capital investment on energy conservation equipment
During the year under review, the Company did not make any specific
capital investments in energy conservation. However, the Company remains committed to
continuously exploring and integrating new technologies and tools aimed at saving energy,
reducing consumption, and utilizing renewable energy sources.
TECHNOLOGY ABSORPTION
(I) Efforts made towards technology absorption a. Updating and
improving processes and systems used for existing products. b. Adopting a green
chemistry-based approach for product development and analysis.
c. Developing and introducing new green novel drug delivery
system technologies to enhance safety, efficacy, bioavailability, and the molecular
ADME properties of both existing and new products.
d. Focusing on the development and launch of new drug delivery
systems, with a special emphasis on lyophilized products
e. Researching and developing novel drug delivery systems such
as microspheres, liposomes, nanoemulsions, etc.
f. Developing various biological products like oral COVID
vaccines, oral dengue vaccines, etc.
g. Working on more than 70 products for domestic and regulated
markets, with comprehensive R&D detailing and market research data
h. Maintaining product quality from initial R&D by utilizing
a Quality by Design (QbD) approach for regulated markets. i. Filing patents for
different NDDS-based projects, including liposomes, nanoemulsions, etc. j. Conducting
accelerated and real-time stability studies of products to ensure quality throughout
their shelf life.
(II) Benefits derived as a Result of R & D
a. Successfully launched more than 30 Generic products in the domestic
and international market in the financial year 2023-24.
b. About 25 products are poised for commercialisation in the financial
year 2024-25.
c. More than 70 New products are under development.
d. Development of new drug delivery systems and devices to improve
patient benefit.
e. Development of products for import substitution.
(III) In case of imported technology (imported during the last three
years reckoned from the beginning of the financial year)
Details of technology imported |
Year of Import |
Whether the technology has been fully
absorbed |
If not fully absorbed, areas where
absorption has not taken place, and the reasons thereof |
Penem Product in dual chamber bag |
2020-21 |
Yes |
Product Launched |
Super purified Menotropin |
2021-22 |
Yes |
Product Launched |
Super purified Urofollitropin |
2023-24 |
No |
Product under development |
(IV) Expenditure incurred on Research and Development
in Lakhs
Particulars |
2023-24 |
2022-23 |
Capital Expenditure |
124.84 |
214.17 |
Revenue Expenditure |
541.25 |
515.59 |
Total |
666.09 |
729.76 |
FOREIGN EXCHANGE EARNINGS AND OUT-GO
|
|
in Lakhs |
Particulars |
2023-24 |
2022-23 |
Earnings in foreign currency |
9,105.15 |
8,603.22 |
Out-go in foreign currency |
20,483.07 |
27,156.19 |
RISK MANAGEMENT
The Company has in place a Risk Management Policy and framework to
identify and assess risks associated with the business and ensure that there exists a
proper management process to mitigate or minimize the same. The Board has constituted Risk
Management Committee which oversees the implementation of Risk Management policy as well
as risk management and mitigation framework. As on March 31, 2024, the Risk Management
Committee comprises of 7 (Seven) members which is in compliance with the provisions of the
Act and SEBI Listing Regulations. The Committee also diligently monitors and reviews the
effectiveness of the risk management plan on an ongoing basis. Additionally, the Audit
Committee also have an oversight on financial risks. Together, these committees ensures
that a robust risk management framework is in place.
Your Board of Directors reviews the risk management policy, at least
once in two years, to adapt to evolving industry dynamics and increasing complexity. The
Company takes a proactive approach to risk mitigation, systematically addressing major
risks through appropriate actions and measures.
The risk management policy adopted by the Company can be accessed on
the Company's website at
http://gufic.com/wp-content/uploads/2024/08/Risk-Management-Policy.pdf
The details pertaining to composition of the Risk Management Committee
along with the meetings held during the year and other details are included in the Report
on Corporate Governance, which forms part of this Annual Report.
PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES
In terms of the provisions of Section 197(12) of the Act read with Rule
5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014,
disclosures pertaining to remuneration and other details are provided in Annexure
- D to this Report.
VIGIL MECHANISM / WHISTLE BLOWER POLICY
In accordance with Section 177 of the Act read with Rule 7 of the
Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 22 of the SEBI
Listing Regulations, the Company has in place a vigil mechanism i.e. Whistle Blower Policy
for directors and employees to report genuine concerns about unethical behavior, actual or
suspected violation, malpractices, corruption, fraud or unethical conduct, leak of
unpublished price sensitive information, violation of Code of Conduct, etc. to the
Chairperson of Audit Committee without any fear of reprimand, retaliation, victimization
or unfair treatment.
The Vigil Mechanism provides for direct access to the Chairperson of
the Audit Committee. The policy is reviewed by the Audit Committee from time to time. The
details of the policy are made available on the website of the Company at the following
link: http://gufic.com/wp-content/uploads/2016/08/WHISTLE_BLOWER_POLICY.pdf.
It is affirmed that during the financial year 2023-24, no employee or
director was denied access to the Audit Committee. Further, no concerns or irregularities
have been reported by employees/directors till date.
SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS
During the year under review, no significant or material orders were
passed by the regulators or courts or tribunals which could impact the 'going concern'
status and the future operations of the Company.
AUDITORS & AUDIT REPORT
a) Statutory Auditor
M/s. Mittal Agarwal & Co., Chartered Accountant (FRN: 131025W)
were appointed as the Statutory Auditors of theCompany by the Shareholders at the 36 AGM
of the Company to hold office for a period of 5 (five) consecutive yearscommencing from
the conclusion of the 36 AGM until the conclusion of 41 AGM. The Statutory Auditors have
confirmed their independent status and eligibility to act as a Statutory Auditor of the
Company, pursuant to applicable provisions of the Act. They have also confirmed that they
hold a valid certificate issued by the Peer Review Board of the ICAI, pursuant to SEBI
Listing Regulations.
Auditor's Report for the year under review forms part of this
annual report. There is no qualification, reservation or adverse remark in their report on
Financial Statement for FY 2023-24. The Notes on financial statements referred to in
Auditor's Report are self-explanatory and do not call for any further comments.
b) Cost Auditor
The Company is required to maintain Cost Records as specified by
the Central Government under Section 148(1) of the Act and accordingly, such accounts and
records are made and maintained by the Company.
The Board has, on recommendation of Audit Committee, appointed M/s.
Kale & Associates, Cost Accountants, Mumbai (Firm Registration No. 001819) to audit
the cost records of the Company for the financial year 2024-25 pursuant to Section 148 and
other applicable provisions, if any, of the Act read with Companies (Audit and Auditors)
Rules, 2014 and Companies (Cost Record and Audit) Rules, 2014 (including any statutory
modification(s) or re-enactments thereof, for the time being in force). The Cost Auditors
have confirmed that their appointment is in accordance with the applicable provisions of
the Act and rules framed thereunder and that they are not disqualified to be appointed as
the Cost Auditors of the Company for the year ending March 31, 2025. As per the said
provisions, the remuneration payable to the Cost Auditors is required to be ratified by
the shareholders at the ensuing AGM. Accordingly, a resolution seeking ratificationby
members for their remuneration, forms part of the Notice convening 40 AGM. The Board
recommends the same for approval of Members.
In compliance with Section 148 of the Act and Rule 6 of the Companies
(Cost Records and Audit) Rules, 2014, Cost Audit Report in the Form CRA - 4 (XBRL mode)
for the financial year ended March 31, 2023, was filed by the Company with the Central
Government on October 05, 2023. The Cost Auditors' Report for the financial year
2022-23 does not contain any qualification, reservation or adverse remark. The Cost Audit
Report for the year ended March 31, 2024 shall be filed within the prescribed timeline in
due course.
c) Secretarial Auditor
Pursuant to the provisions of Section 204 of the Act read with the
Companies (Appointment and Remuneration on Managerial Personnel) Rules, 2014 and
Regulation 24A of SEBI Listing Regulations, the Board of Directors of the Company
appointed M/s. Manish Ghia & Associates, Practicing Company Secretary to undertake the
Secretarial Audit of the Company for the financial year 2023-24.
The Secretarial Audit Report for the financial year 2023-24 does not
contain any qualification, reservation or adverse remark. The Secretarial Audit Report are
self-explanatory and do not require any further explanation. The Secretarial Audit Report
in the prescribed Form No. MR 3 is annexed to this Report as Annexure E.
The Annual Secretarial Compliance Report for the financial year ended
March 31, 2024, in relation to compliance of all applicable SEBI Regulations/circulars/
guidelines issued thereunder, pursuant to requirement of Regulation 24A of SEBI Listing
Regulations, was submitted to the concerned Stock Exchange(s) on May 21, 2024 which is
within the prescribed timeline. The said Report does not contain any qualification,
reservation or adverse remark.
d) Internal Auditor
The Company has its in-house Internal Audit team within the
organization led by the Chief Internal Auditor, Mrs. Saroj R. Kirdolia, Chartered
Accountant .
Significant audit observations and corrective actions by the Internal
Auditor thereon are presented to the Audit Committee of the Board and reviewed on
quarterly basis. Based on report of Internal Audit function, corrective actions in the
respective area are undertaken & controls are strengthened.
COMPLIANCE WITH SECRETARIAL STANDARDS
During the year under review, the Company has complied with all the
applicable mandatory Secretarial Standards, as amended from time to time, issued by the
Institute of Company Secretaries of India (ICSI).
ANNUAL RETURN
Pursuant to Section 92(3) read with Section 134(3) (a) of the Act, the
Annual Return as on March 31, 2024 is available on the Company's website at :
https://gufic.com/Notice/Annual%20Return%202023-24%20Form%20MGT%207.pdf
MANAGEMENT DISCUSSION & ANALYSIS REPORT
The Management Discussion and Analysis Report as prescribed under Part
B of Schedule V read with Regulation 34 of the SEBI Listing Regulations is provided in a
separate section and forms part of this Report.
BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT
The Business Responsibility and Sustainability Report of the Company
for the Financial Year 2023-24 forms a part of this Annual Report as required under
Regulation 34(2)(f) of SEBI Listing Regulations. The Board of Directors have also adopted
a Business Responsibility and Sustainability Policy (BRSR Policy) which is
available on the website of the Company at
http://gufic.com/wp-content/uploads/2023/05/Business%20Responsibility%20Policy.pdf
REPORT ON CORPORATE GOVERNANCE AND CERTIFICATE
The Company demonstrates unwavering dedication to upholding the utmost
standards of Corporate Governance and diligently follows the regulations prescribed by the
Securities and Exchange Board of India (SEBI). Furthermore, the Company have
integrated numerous exemplary governance practices and aims to continually augment
long-term shareholder value while ensuring utmost regard for minority rights in every
aspect of our business choices.
Report on Corporate Governance along with certificate received from
M/s. Manish Ghia & Associates, Practicing Company Secretaries and Secretarial Auditors
of the Company confirming compliance of conditions of Corporate Governance for the year
ended March 31, 2024 forms part of this Annual Report.
CYBER SECURITY INCIDENCE
Due to the rising frequency of cyber attacks, your Company periodically
reviews the cyber security maturity and continuously enhance the processes and technology
controls to align with evolving threat scenarios. Your Company's technology
environment is equipped with real-time security monitoring and essential controls across
end user machines, network, applications and data layers.
Cyber security constitutes a critical component of our risk management
framework and receives focused attention from the Board of Directors and management.
Additionally, the Board of Directors receives periodic reports on our cyber security
incidents as needed.
PREVENTION OF SEXUAL HARASSMENT AT WORK PLACE
Prevention of Sexual harassment forms an integral part of our
commitment to provide an equal opportunity and harassment-free workplace. Your Company has
established an Internal Complaints Committee (ICC) dedicated to promptly
addressing sexual harassment complaints and ensuring their timely resolution. We uphold a
zero-tolerance policy towards sexual harassment.
Your Company has adopted a comprehensive policy on the prevention,
prohibition, and redressal of sexual harassment which is 18 aligned with Sexual Harassment
of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH
Act) and Rules framed thereunder. This policy outlines clear guidelines for the
redressal and investigation processes to be followed by complainants and the ICC when
handling sexual harassment issues in the workplace. The policy extends its coverage to all
employees, including permanent, temporary, contractual and trainees. New employees
participate in detailed orientation programs designed to raise awareness and foster
sensitivity, contributing to a respectful workplace environment.
During the year under review, no complaints of sexual harassment were
reported to the Company. The Company has duly submitted the Annual Returns to the relevant
local authorities, as mandated by the POSH Act.
GREEN INITIATIVE
As a responsible Corporate Citizen, the Company embraces the
Green Initiative' undertaken by the Ministry of Corporate Affairs, Government
of India, enabling electronic delivery of documents including the Annual Report and
Notices to the Shareholders at their e-mail address registered with the Depository
Participant (DPs) and Registrar and Share Transfer Agent.
We would greatly appreciate and encourage more Members to register
their email address with their Depository Participant or the RTA / Company, to receive
soft copies of the Annual Report and other information disseminated by the Company.
Shareholders who have not registered their e-mail addresses so far are requested to do the
same. Those holding shares in demat form can register their e-mail address with their
concerned DPs. Shareholders who hold shares in physical form are requested to register
their e-mail addresses with the RTA/ Company, by sending KYC updation forms duly signed by
the shareholder(s) with required details.
We invite Shareholders who haven't registered their e-mail
addresses to join this initiative and support environment sustainability.
HUMAN RESOURCES
Your Company values its employees as crucial resources driving the
organization's growth. The Company takes pride in the commitment, competence and
dedication exhibited by its employees across all facets of our operations.
Attracting, developing and retaining top talent remains a key strategic
imperative and the organization maintains a steadfast focus in this regard. We have
established objective and transparent processes for Recruitment, Selection, Performance
Management and Talent Management.
In our competitive industry, we recognize the importance of cultivating
a workforce that is consumer-focused, performance-driven and future-ready. The Company is
dedicated to nurturing, enhancing and retaining our top talent through robust learning and
organizational development initiatives, fostering a performance culture that enables our
people to thrive. Moreover, the Company has fortified its focus on enhancing the overall
well-being of the employees.
Industrial relations remained cordial throughout the year under review.
CODE FOR PREVENTION OF INSIDER TRADING
The Board of Directors has formulated a Code of Conduct for Insiders
(Code of Conduct) and the Code of Practices and Procedures for Fair
Disclosure of Unpublished Price Sensitive Information (Code of Fair
Disclosure) to regulate, monitor and report trading activities by its designated
person and their immediate relatives. The Company also maintains a Policy on Code of
Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information
(UPSI). This Policy specifies the procedures to be followed by Designated Persons while
dealing in shares of the Company when in possession of UPSI. The Codes outlines their
obligations and responsibilities of Designated Persons, maintenance of the structured
digital database, pre-clearance procedures, mechanism to prevent insider trading, handling
and disclosure of UPSI for legitimate purposes, consequences of violations. The Company
has also maintained Structured Digital Database (SDD) to ensure compliance with the
statutory requirements. The Company ensures that the Designated Persons are familiarized
about the Code of Conduct and trained on maintaining SDD. Further, the Compliance Officer
has received requisite disclosure from the Directors and Designated Persons in compliance
with the Code from all the designated persons.
The aforementioned Codes can be accessed on the website of the Company
at the following web link:
Code of Fair Disclosure:
http://gufic.com/wp-content/uploads/2016/08/Code%20of%20Fair%20Disclosure%20and%20determination%20of%20Legitimate%20Purpose.pdf
CREDIT RATING
The details of the Credit Rating received by the Company have been
provided in the Report on Corporate Governance, forming part of this Annual Report.
GENERAL DISCLOSURES
During the year under review, the Board of Directors confirm that no
disclosure or reporting is necessary for the following, as there were no transactions /
events of such nature: a. no application has been made under the Insolvency and Bankruptcy
Code, 2016, as amended, hence, the requirement to disclose the details of application made
or any proceeding pending under the said Code along with their status as at the end of the
Financial Year is not applicable.
b. the requirement to disclose the details of difference between amount
of the valuation done at the time of one-time settlement and the valuation done, while
taking loan from the Banks or Financial Institutions along with the reasons thereof, is
not applicable as there was no such valuation done.
c. there was no revision of financial statements and Board's
Report of the Company.
d. the Company has not failed to implement any corporate action.
e. there were no agreements entered by the Company which comes within
the purview of Regulation 30A of SEBI Listing Regulations.
f. the trading of securities of the Company were not suspended by the
stock exchanges.
ACKNOWLEDGEMENTS
Your Board of Directors extends its heartfelt appreciation and
acknowledgement to all stakeholders, employees and partners whose dedication and
commitment have been instrumental in achieving significant milestones for Gufic. We
recognize the relentless efforts and resilience demonstrated by our employees across all
levels, whose hard work and dedication have propelled us towards our business goals. This
past year has seen notable achievements, thanks to the collective efforts of our team and
the unwavering support of our stakeholders. We remain committed to nurturing these
relationships and pursuing growth opportunities together.
We are deeply grateful to our shareholders for their continued trust
and support in our strategic direction. Their support has been integral to our consistent
progress and success. Our partnerships with customers, suppliers, and business associates
have proven invaluable, providing crucial support and collaboration that enabled us to
navigate challenges and sustain our position in the industry.
In conclusion, we sincerely appreciate everyone involved in
Gufic's journey. Together, we look forward to a future marked by sustained growth and
shared success.
|
For and on behalf of the Board of
Directors |
|
of Gufic Biosciences Limited |
|
Sd/- |
|
Jayesh P. Choksi |
Place: Mumbai |
Chairman & Managing Director |
Date: August14, 2024 |
DIN: 00001729 |